![]() ![]() Indian pharmaceutical industry at present ![]() In the span of three decades from the 1950s through the 1970s, the Indian pharmaceutical industry has grown from its formerly meager existence, with a low production base, heavy dependence on imports, domination by foreign firms and high prices of drugs, to being one of the largest pharmaceutical industries in the world. The pharma industry in India emerged as the most dynamic technological content segment in the Indian manufacturing in the 1990s. As a result, pharmaceutical industry in India turned to a mass production of generics of every imaginable nature. In order to tackle this situation and overcome the challenges, Indian entrepreneurs received an enormous support from the government to fill this void in the pharmaceutical industry. Looking at the early years, the Indian pharmaceutical industry in 1950s had limited resource and opportunities, with few technological capabilities to manufacture modern drugs, locally. By late 2000, over 50 per cent revenue for major Indian manufacturers was from International markets. Once domestic market was conquered by local companies, there was a need to spread their wings in international market in late 80s and early 90s. At that time, most medicines were imported into India and market was dominated by MNCs. ![]() The company’s Consumer Healthcare (CHC) business division develops and markets over-the-counter (OTC) products in India and employed 38,000 people.While talking about the beginning of Indian pharmaceutical industry, it begun in the late 50s and early 60s, out of the need to meet local shortages and bring down the cost. Sun Pharma classifies its business into three categories namely, Formulations, API, and Others. The company reported revenue of $4,533 million with average revenue growth of 2.1%. The company manufactures and supplies more than 400 generic (branded and non-branded) pharmaceuticals to treat conditions such as diabetes, central nervous system disorders, central vascular system disorders, and respiratory and infectious diseases, and markets these drugs in various dosage forms such as tablets/capsules, semi-solids, liquids, and suppositories. India-based Sun Pharmaceutical Industries Ltd is one of the top Global Generic Companies in 2021 by revenue (FY 2021). The company reported revenue of $16,659 million and employed 34,713 people. The company provides specialty medicines to treat disorders of the central nervous system (CNS), respiratory, dermatology, cancer, women’s health, and other disease conditions. It discovers, develops, manufactures, and commercializes generic and specialty medicines. Israel-based Teva Pharmaceutical Industries Ltd is one of the top Global Generic Companies in 2021 by revenue (FY 2021). They employed a total of 173,859 people in 2021. In terms of the geographical split, 9 out of 10 Global Generic Companies are based in Asia, while 1 is based in North America. The highest revenue growth was registered by Towa Pharmaceutical Co Ltd (40.33%), followed by Cipla Ltd (11.84%), while Teva Pharmaceutical Industries Ltd reported a decline in its revenues by 4.69%. Cumulatively, the top 10 Global Generic Companies generated revenue of $37,454 million, with average revenue growth of 6.97%, the highest revenue was generated by Teva Pharmaceutical Industries Ltd ($16,659 million), followed by Sun Pharmaceutical Industries Ltd ($4,533 million) and Cipla Ltd ($2,593 million). Reddy's Laboratories Ltd, and Lupin Ltd are the top 5 Global Generic Companies in 2021 by revenue. Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Cipla Ltd, Dr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |